Global R&D Pipeline
My Favorite
Hot Targets:
PTK7
Back
Total number of drugs
25
Phase II and later clinical stages
4%
Involving companies
41
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NM-04 | NM-04 | Nanobody | Neoplasms Digestive System Disorders Urogenital Diseases | PTK7 inhibitors | NanoMab Technology Ltd. | - | Discontinued (in Preclinical) | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | NM-04 | - | - | detail > | |
| OI-1 | OI-1 | Monoclonal antibody | Neoplasms | PTK7 inhibitors | Oncoinvent ASA (Old) | Oncoinvent ASA (Old) | Preclinical | - | - | - | - | - | - | - | - | - | OI-1 | - | - | detail > | |
| BCG-033 | BCG-033 | Antibody drug conjugate (ADC) | Neoplasms Digestive System Disorders Respiratory Diseases Skin and Musculoskeletal Diseases | PTK7 inhibitors Trop-2 inhibitors Tubulin inhibitors | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Biocytogen Boston Corp. | Preclinical | Preclinical | - | - | - | - | - | - | MMAE | 8 | BCG-033 | - | - | detail > | |
| DEC-006 | DEC-006 | Antibody drug conjugate (ADC) | Neoplasms Endocrinology and Metabolic Disease Respiratory Diseases Urogenital Diseases | PTK7 modulators | WuXi AppTec Biotechnology Co., Ltd. Hangzhou DAC Biotechnology Co., Ltd. | Whitehawk Therapeutics, Inc. Hangzhou DAC Biotechnology Co., Ltd. WuXi AppTec Biotechnology Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | DEC-006 | - | - | detail > | |
| HWK-007 | HWK-007 | Antibody drug conjugate (ADC) | Neoplasms Endocrinology and Metabolic Disease Respiratory Diseases Urogenital Diseases | PTK7 modulators | Whitehawk Therapeutics, Inc. | Whitehawk Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | HWK-007 | - | - | detail > | |
| IDE034 | IDE034 | Antibody drug conjugate (ADC) | Neoplasms | CD276 inhibitors PTK7 inhibitors | IDEAYA Biosciences, Inc. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. IDEAYA Biosciences, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | IDE034 | - | - | detail > | |
| Anti PTK7 specific antibody(Kelun-Biotech) | Anti PTK7 specific antibody(Kelun-Biotech) | Monoclonal antibody | Neoplasms | PTK7 modulators | Sichuan Kelun Botai Biomedicine Co., Ltd. | Sichuan Kelun Botai Biomedicine Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | Anti PTK7 specific antibody(Kelun-Biotech) | - | - | detail > | |
| DM003 | DM003 | Antibody drug conjugate (ADC) | Neoplasms | EGFR modulators PTK7 inhibitors | Doma Biopharmaceutical Suzhou Co. Ltd. | - | Discontinued (in Discovery) | Discontinued (in Discovery) | - | - | - | - | - | - | - | - | DM003 | - | - | detail > | |
| Anti-PTK7 CAR-T cell therapy (CRISPR Therapeutics) | Anti-PTK7 CAR-T cell therapy (CRISPR Therapeutics) | CAR-T | Neoplasms | PTK7 modulators | CRISPR Therapeutics AG | - | Pending (in Preclinical) | - | - | - | - | - | - | - | - | - | Anti-PTK7 CAR-T cell therapy (CRISPR Therapeutics) | - | - | detail > | |
| 68Ga-Sgc8 | 68Ga-Sgc8 | Aptamer drug conjugates | Neoplasms Digestive System Disorders | PTK7 inhibitors | Xijing Hospital | - | Pending (in Phase 1) | Pending (in Phase 1) | - | - | - | - | - | NODA | 68 Ga | - | 68Ga-Sgc8 | - | - | detail > |
Total 25 data
1
2
3
